Gain Therapeutics, Inc. [Rocket]

In millions, except per share items	Dec-31-22	Dec-31-21	Dec-31-20	Dec-31-19	Dec-31-18
	8-K	10-K	10-K	S-1/A	S-1/A
Revenues [+]	0.1	0.2	0.0	0.0	0.0
Royalties	-8.4			-1.6	-0.8
Other				0.0	0.0
Revenue growth	-15.1%	471.3%	-30.1%	100.4%
Cost of goods sold	17.9	0.0	0.0	1.6	0.8
Gross profit	-17.8	0.2	0.0	-1.5	-0.8
Gross margin	-12688.1%	100.0%	100.0%	-3740.7%	-3912.2%
Selling, general and administrative [+]	9.5	6.8	1.2	0.6	0.2
General and administrative	9.5	6.8	1.2	0.6	0.2
Research and development		7.2	2.3
Other operating expenses	-9.5
EBITDA [+]		-13.8	-3.5	-2.1	-1.0
EBITDA growth	28.7%	298.0%	65.4%	104.1%
EBITDA margin	-12688.1%	-8370.4%	-12014.3%	-5078.7%	-4986.1%
Depreciation and amortization		0.0	0.0	0.0	0.0
EBIT [+]	-17.8	-13.8	-3.5	-2.1	-1.0
EBIT growth	28.6%	297.4%	65.7%	104.2%
EBIT margin	-12688.1%	-8379.8%	-12047.5%	-5084.9%	-4989.7%
Interest income, net [+]	0.4	0.0	0.0	0.0	-0.1
Interest expense				0.0	0.1
Interest income	0.4	0.0	0.0
Other income (expense), net [+]	-0.1	-0.1	-0.1	-0.1	0.0
Gain (loss) on foreign currency transactions	-0.1	-0.1	-0.1
Pre-tax income	-17.5	-13.9	-3.6	-2.2	-1.1
Income taxes	0.1	0.0	0.0	0.0	0.0
Net income	-17.6	-13.9	-3.6	-2.2	-1.1
Net margin	-12555.1%	-8418.9%	-12387.7%	-5310.9%	-5364.4%

Basic EPS [+]	($1.48)	($1.37)	($1.33)	($0.97)	($0.49)
Growth	8.3%	2.4%	36.9%	98.4%
Diluted EPS [+]	($1.48)	($1.37)	($1.33)	($0.97)	($0.49)
Growth	8.3%	2.4%	36.9%	98.4%

Shares outstanding (basic) [+]	11.9	10.2	2.7	2.3	2.3
Growth	16.9%	279.1%	19.2%	0.0%
Shares outstanding (diluted) [+]	11.9	10.2	2.7	2.3	2.3
Growth	16.9%	279.1%	19.2%	0.0%

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.